Purified and concentrated Venezuelan equine encephalitis (VEE) preparations to confer protection in animals was investigated, and the results are presented in this report.
Purified and concentrated Venezuelan equine encephalitis (VEE) virus derived from tissue cultures, rendered noninfectious by ionizing radiation with retention of in vitro serological activity, also retained a high level of immunogenicity. In mice, fluid vaccines afforded excellent protection against lethal challenge with homologous Trinidad strain VEE virus. A direct relationship was observed between concentration of vaccine or number of injections and survival. One intraperitoneal inoculation of undiluted vaccine protected essentially all mice challenged 21 days later with 100,000 mouse intraperitoneal LD50 of virus. Similarly, mice receiving three injections of vaccines diluted 1:100 were completely protected. Noninfectious VEE virus preparations combined with adjuvant 65, a nontoxic metabolizable vehicle, were likewise very effective in protecting mice immunized intraperitoneally or subcutaneously against lethal challenge. Guinea pigs immunized subcutaneously with adjuvantcombined vaccine survived lethal challenge of 1,000,000 guinea pig intraperitoneal LD50. Existing vaccines for the protection of laboratory personnel potentially exposed to Venezuelan equine encephalitis (VEE) virus include several Formalin-inactivated preparations (8, 10; Smith et al., Bacteriol Proc., p. 59, 1954.) and a live, attenuated vaccine (2) . Unfortunately, the Formalin-treated VEE vaccines either contain residual infectious virus (15) or are so drastically treated as to confer inadequate protection (2, 7) . The live, attenuated vaccine, although conferring good protection in man (7) , causes a significant incidence of undesirable clinical manifestations (1) . An experimental tissue culture vaccine inactivated by ionizing radiation was recently described (13) .
In studies to develop a more effective nonviable VEE vaccine, we have investigated the applicability of two approaches not previously utilized in conjunction: purification and concentration of virus by diethylaminoethyl (DEAE) cellulose chromatography and inactivation by ionizing radiation. The procedure proved applicable to obtaining purified and inactivated VEE virus preparations that retained significant in vitro serological reactivity (4) . The capability of these serologically active noninfectious virus 1 Present address: Viral Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md. 20014. preparations to confer protection in animals was investigated, and the results are presented in this report.
MATERIALS AND METHODS Virus. The Trinidad strain of VEE virus, originally isolated in guinea pigs from a donkey brain (9), was used. It had been passaged 13 times in chicken embryos when it was obtained through the courtesy of our colleague William P. Allen. Working seeds for these studies were prepared from a second suckling mouse brain passage as 10% suspensions of infected suckling mouse brains in 7.5% bovine serum albuminborate saline.
Infectivity and antigenicity determinations. Assays for virus infectivity were performed by plaque titration in 24-hr chick embryo monolayer tissue cultures (CETC) and by titration of lethality in 10-to 12-g weanling mice. Samples of irradiated virus that failed to produce plaques in tissue culture and were nonlethal for weanling mice after joint intracerebralintraperitoneal inoculation (0.03 and 0.1 ml) were titrated in suckling mice for residual live virus by a combination intracerebral and intraperitoneal inoculation of 0.02 and 0.03 ml, respectively (12) . Fifty per cent lethal dose end points (LD50) were calculated by the method of Reed and Muench (11) . Assays for viral hemagglutinins (HA) and complement-fixing (CF) antigens were performed using microtiter methods (3, 14 (4) . This method and dose of radiation were used to inactivate the vaccines used in this investigation. The inactivation of virus preparations typically obtained is indicated in Table 1 . As reported previously, inactivation of infectivity was linear and complete at 6 X 106; in contrast, both HA and CF in vitro antigenicities were usually fully retained.
All the vaccines examined were prepared from chromatographed virus preparations of similar infectivity levels. Table 2 lists the seven vaccines studied, their initial infectious virus content, and the HA and CF antigen activity retained after inactivation. All the vaccines tested were comparable in initial viral infectivity titers and viral antigen content.
The several vaccines were carefully examined for residual live virus after irradiation by tests performed in both tissue culture and animal systems. Usually, at least 10% of a total vaccine Vaccines with adjuvant. The effectiveness of these nonviable purified VEE virus preparations in combination with adjuvant was investigated. In an initial study, seven 10-to 12-g weanling mice were inoculated intraperitoneally with 0.5 ml of an emulsion of equal parts of fluid (saline) vaccine and adjuvant 65 (vaccine IAS). Twenty-one days later they were challenged with 5,000 MIPLD50 of Trinidad strain VEE virus. The combination vaccine protected all immunized mice. All nonimmunized mice and control mice receiving adjuvant 65 alone failed to survive simultaneous challenge.
In a more extensive study, two groups of 25 adult (18 to 20 g) mice were immunized via the subcutaneous route with either one or two injections of vaccine combined with adjuvant (IIAH). As before, the combination vaccine consisted of an emulsion of equal parts of fluid (histidine) vaccine and adjuvant 65. The fluid vaccine used in this study was the fourth vaccine derived from an independent tissue culture harvest, column purification, and inactivation. The volume of combined vaccine injected was 0.5 ml, and the multiple injections were 28 days apart. Immunizations were spaced so that both groups of mice were challenged simultaneously. Protection was assayed by intraperitoneal injection of 100,000 MIPLD50 of Trinidad strain VEE virus 21 days after the last immunizing injection. Results are presented in Table 5 . The combination vaccine afforded the mice excellent protection. All 25 mice that received two immunizations and 24 of the 25 mice that were inoculated only once survived challenge. Furthermore, none of the 49 surviving mice demonstrated any signs of illness. In contrast, all nonimmunized control mice and mice injected with adjuvant 65 alone failed to survive simultaneous challenge. Immunization of guinea pigs. To determine further the protection conferred by these adjuvant-combined nonviable VEE vaccines, immunogenicity studies were extended to include the guinea pig. This species was selected because it made available for further serological and pathological studies a 10-fold larger animal and also because of the guinea pig's marked sensitivity to lethal VEE virus infection. Two groups of 15 young adult guinea pigs (250 to 300 g) were immunized by one or two subcutaneous inoculations of 0.5 ml of a new adjuvant-combined vaccine (IIIAH). The fluid-virus portion of this vaccine represented the fifth independent growth, purification, and inactivation of VEE virus. Multiple injections were spaced 28 days apart, and immunizations were scheduled so that both groups of guinea pigs were challenged at the same time. Immunogenicity was determined by protection from a lethal intraperitoneal challenge of 1,000,000 GPIPLD50 of Trinidad strain VEE virus 21 days after the last immunizing injection. Results are given in The immunogenic potency of the nonviable vaccines described in this report is similar to that of other recently described VEE vaccines that were also inactivated by ionizing radiation (13 
